A highly anticipated clinical trial combining two immunotherapy drugs failed to delay tumor growth in patients with newly diagnosed lung cancer, sending AstraZeneca sharply lower Thursday.
The negative results from the so-called MYSTIC study are a stinging setback to AstraZeneca’s ambition to leapfrog over its cancer immunotherapy rivals.
￼I solved the cancer problem years ago. Cancer could be cured and/or prevented
￼by combined gene therapy and eye drops with dorzolamide. Other approaches
￼with toxic drugs are deliberate fraud or innocent mistakes.
￼Michael I. Lerman, M.D., Ph.D.
Cancer causing Genes Expert,
Laboratory of Immunobilogy, NCI, USA, 1980-2008,
Board Member, Affina Biotechnologies, Inc., USA, present
Email: [email protected]
Comments are closed.